Company intelligence
Rondo Therapeutics
Our bispecific antibodies are designed with broad therapeutic windows, sparing healthy tissue while eradicating tumors.
About Rondo Therapeutics
At Rondo Therapeutics we believe that our success as a company starts with building a culture based on teamwork, trust, career growth, and a sense of fun. We develop innovative bispecific antibody therapies, specifically targeting unmet needs in solid tumors. Our bispecific antibodies are designed with broad therapeutic windows, sparing healthy tissue while eradicating tumors. If you are a fearless scientist driven to make new discoveries and you value collaboration, respect, and working in a team environment, then we want to hear from you! Join us in our mission to create novel molecules that bring new hope to cancer patients while advancing your career in a merit-based culture.
Verified activity
Signals from Rondo Therapeutics
2 published signals
Research & Knowledge
Rondo Therapeutics announced positive Phase 3 results for etentamig (ABBV-383) in relapsed/refractory multiple myeloma, showing a 74% objective response rate versus 46% for standard therapies.
Reported by Katherine Harris
Research & Knowledge
Rondo Therapeutics believes innovation in co-stimulatory bispecific antibodies represents an exciting frontier in immuno-oncology.
Reported by Rondo Therapeutics